Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23884534 | 1.00 | AKR1C1 (0.37) | AKR1C1LMNAGAACYP2D6SRC | |
| SCHEMBL11243304 | 0.84 | LMNA (0.37) | AKR1C1LMNAGAASLC6A2SLC6A3 | |
| SCHEMBL10992272 | 0.80 | LMNA (0.37) | LMNASLC6A2SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL11239413 | 0.80 | LMNA (0.37) | LMNASLC6A2SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL28507597 | 0.79 | LMNA (0.36) | LMNASLC6A2SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL10991133 | 0.71 | BRD4 (0.38) | GAACYP2D6SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL13715066 | 0.71 | ARG1 (0.34) | — | |
| SCHEMBL8016763 | 0.71 | ARG1 (0.34) | — | |
| SCHEMBL11241583 | 0.70 | KMT2A (0.38) | CYP2D6ALDH1A1TSHRTDP1NPSR1 | |
| SCHEMBL5696301 | 0.70 | CNR2 (0.39) | AKR1C1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191705-A1 | NON-CANONICAL INSULINS AND THEIR USES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| EP-4525919-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12214018-B2 | Glucose responsive insulins | PROTOMER TECHNOLOGIES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240374735-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2008128064-A2 | TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118848-A1 | N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116054-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | AKR1C1 3256/4885LMNA 1857/4885GAA 47/4885 |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | AKR1C1 2547/4885LMNA 4196/4885GAA 648/4885 |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | IAPP, GPR119, INSR | AKR1C1 1316/4885LMNA 1702/4885GAA 48/4885 |
| US-12214018-B2 | Glucose responsive insulins | GLP1R, GPR119, IAPP | AKR1C1 2567/4885LMNA 4296/4885GAA 661/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | AKR1C1 1951/4885LMNA 1531/4885GAA 1667/4885 |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | GPR119, INSR, IAPP | AKR1C1 1161/4885LMNA 1352/4885GAA 72/4885 |
| US-20240374735-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | IAPP, GPR119, BRCA1 | AKR1C1 1064/4885LMNA 848/4885GAA 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.